Dan Skovronsky (Eli Lilly via Facebook)

Don't get too ex­cit­ed about Eli Lil­ly's up­com­ing Alzheimer's read­out just yet, R&D chief cau­tions

Eli Lil­ly will have re­sults soon from yet an­oth­er test it’s con­duct­ing on the amy­loid be­ta hy­poth­e­sis in Alzheimer’s. But don’t get your hopes up just yet.

In an un­usu­al move, R&D chief Dan Skovron­sky played down ex­pec­ta­tions for the DI­AN-TU tri­al, which en­rolled 490 pa­tients with a ge­net­ic mu­ta­tion that puts them at high­er risk for ear­ly on­set dis­ease. The place­bo-con­trolled study is eval­u­at­ing their solanezum­ab and Roche’s gan­tenerum­ab, both of which had failed de­ci­sive­ly in treat­ing ear­ly-stage Alzheimer’s.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters